MedTrace Logo

Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

NCT00350948 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2013-11-27

No results posted yet for this study

Summary

The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

Telcyta

Day 1 of 28 day Cycle.

DRUG

Liposomal Doxorubicin

Day 1 of 28 Day Cycle. 50 mg/m2

Sponsors & Collaborators

  • Telik

    lead INDUSTRY

Principal Investigators

  • Gail L. Brown, MD, MBA · Telik

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States
  • Belgium
  • Brazil
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00350948 on ClinicalTrials.gov